APO-NITRAZEPAM 5 MG
NITRAZEPAM : 5 MG · DIN 02245230 · APOTEX INC
Health Canada status: DORMANT
What is APO-NITRAZEPAM?
APO-NITRAZEPAM 5 MG contains NITRAZEPAM : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02245230, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 04-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02245230 |
|---|---|
| Brand name | APO-NITRAZEPAM |
| Generic / active ingredient | NITRAZEPAM : 5 MG |
| Manufacturer | APOTEX INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05CD02 NITRAZEPAM |
| AHFS class | 28:24.08 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 04-Aug-2017 |
| Original market date | 2002-09-17 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N05CD02 NITRAZEPAM. 2 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MOGADON | 10 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00511536 |
| MOGADON | 5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00511528 |
| APO-NITRAZEPAM | 10 MG | TABLET | APOTEX INC | DORMANT | DIN 02245231 |
| NITRAZADON | 10 MG | TABLET | AA PHARMA INC | CANCELLED POST MARKET | DIN 02229655 |
| NITRAZADON | 5 MG | TABLET | AA PHARMA INC | CANCELLED POST MARKET | DIN 02229654 |
| NITRAZEPAM-10 | 10 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02255588 |
| NITRAZEPAM-5 | 5 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02255561 |
| SANDOZ NITRAZEPAM | 10 MG | TABLET | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02234007 |
| SANDOZ NITRAZEPAM | 5 MG | TABLET | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02234003 |
Who else supplies NITRAZEPAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NITRAZEPAM appears in 30 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.